{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:20:21Z","timestamp":1788942021750,"version":"build-2803163510"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s41030-025-00303-4","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:04:07Z","timestamp":1752253447000},"page":"365-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis"],"prefix":"10.1007","volume":"11","author":[{"given":"Jaime L.","family":"Rubin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Ghizzi","family":"Pedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Zweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore G.","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"6","key":"303_CR1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/ppul.26954","volume":"59","author":"J Guo","year":"2024","unstructured":"Guo J, King I, Hill A. International disparities in diagnosis and treatment access for cystic fibrosis. Pediatr Pulmonol. 2024;59(6):1622\u201330. https:\/\/doi.org\/10.1002\/ppul.26954.","journal-title":"Pediatr Pulmonol"},{"key":"303_CR2","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","volume":"1","author":"F Ratjen","year":"2015","unstructured":"Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015;1:15010. https:\/\/doi.org\/10.1038\/nrdp.2015.10.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"303_CR3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/ppul.25733","volume":"57","author":"KA McBennett","year":"2022","unstructured":"McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: advances and challenges. Pediatr Pulmonol. 2022;57(1):S5-s12. https:\/\/doi.org\/10.1002\/ppul.25733.","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"303_CR4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/apa.15155","volume":"109","author":"K De Boeck","year":"2020","unstructured":"De Boeck K. Cystic fibrosis in the year 2020: a disease with a new face. Acta Paediatr. 2020;109(5):893\u20139. https:\/\/doi.org\/10.1111\/apa.15155.","journal-title":"Acta Paediatr"},{"issue":"5","key":"303_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","volume":"173","author":"PB Davis","year":"2006","unstructured":"Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006;173(5):475\u201382. https:\/\/doi.org\/10.1164\/rccm.200505-840OE.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"303_CR6","doi-asserted-by":"publisher","first-page":"i95","DOI":"10.1136\/bmjqs-2013-002790","volume":"23","author":"BC Marshall","year":"2014","unstructured":"Marshall BC, Nelson EC. Accelerating implementation of biomedical research advances: critical elements of a successful 10 year Cystic fibrosis foundation healthcare delivery improvement initiative. BMJ Qual Saf. 2014;23(Suppl 1):i95\u2013103. https:\/\/doi.org\/10.1136\/bmjqs-2013-002790.","journal-title":"BMJ Qual Saf"},{"key":"303_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/genes11060589","author":"V Scotet","year":"2020","unstructured":"Scotet V, L\u2019Hostis C, F\u00e9rec C. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. Genes (Basel). 2020. https:\/\/doi.org\/10.3390\/genes11060589.","journal-title":"Genes (Basel)."},{"issue":"1","key":"303_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65\u2013124. https:\/\/doi.org\/10.1016\/s2213-2600(19)30337-6.","journal-title":"Lancet Respir Med"},{"issue":"6 Pt 2","key":"303_CR9","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.lpm.2017.04.012","volume":"46","author":"AL Stephenson","year":"2017","unstructured":"Stephenson AL, Stanojevic S, Sykes J, Burgel PR. The changing epidemiology and demography of cystic fibrosis. Presse Med. 2017;46(6 Pt 2):e87\u201395. https:\/\/doi.org\/10.1016\/j.lpm.2017.04.012.","journal-title":"Presse Med"},{"issue":"6","key":"303_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/mcp.0000000000000520","volume":"24","author":"S Corriveau","year":"2018","unstructured":"Corriveau S, Sykes J, Stephenson AL. Cystic fibrosis survival: the changing epidemiology. Curr Opin Pulm Med. 2018;24(6):574\u20138. https:\/\/doi.org\/10.1097\/mcp.0000000000000520.","journal-title":"Curr Opin Pulm Med"},{"key":"303_CR11","unstructured":"Cystic Fibrosis Foundation Patient Registry. 2023 Annual Data Report. Bethesda, Maryland: U.S. Cystic Fibrosis Foundation; 2024."},{"key":"303_CR12","unstructured":"Ireland CFRo. Cystic Fibrosis Registry of Ireland 2023 Annual Report. Cystic Fibrosis Registry of Ireland; 2025."},{"key":"303_CR13","unstructured":"Canada CF. The Canadian Cystic Fibrosis Registry 2022 Annual Data Report. Toronto, Canada: Cystic Fibrosis Canada; 2023."},{"key":"303_CR14","unstructured":"Australian Cystic Fibrosis Data Registry. Australian cystic fibrosis data registry annual report 2023. 25 ed: Monash University, Department of Epidemiology and Preventive Medicine; 2024."},{"key":"303_CR15","unstructured":"Trust CF. UK Cystic Fibrosis Registry. 2023 Annual Data Report. Cystic Fibrosis Trust; 2024."},{"key":"303_CR16","unstructured":"Cystic Fibrosis Foundation Patient Registry. 2023 Highlights Report. Bethesda, Maryland: U.S. Cystic Fibrosis Foundation; 2024."},{"key":"303_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111769","author":"L Regard","year":"2022","unstructured":"Regard L, Martin C, Burnet E, Da Silva J, Burgel PR. CFTR modulators in people with cystic fibrosis: real-world evidence in France. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11111769.","journal-title":"Cells"},{"key":"303_CR18","unstructured":"KALYDECO (ivacaftor) FDA Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203188s034,207925s013lbl.pdf Accessed 2023."},{"key":"303_CR19","unstructured":"FDA Approves KALYDECO\u2122 (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis. 2012."},{"key":"303_CR20","unstructured":"ORKAMBI (lumacaftor and ivacaftor) FDA Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206038s016lbl.pdf. Accessed 2023."},{"key":"303_CR21","unstructured":"SYMDEKO (tezacaftor\/ivacaftor) FDA Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210491s007lbl.pdf. Accessed 2023."},{"key":"303_CR22","unstructured":"TRIKAFTA (elexacaftor, tezacaftor, ivacaftor) FDA Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf. Accessed 2023."},{"issue":"19","key":"303_CR23","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele. N Engl J Med. 2019;381(19):1809\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1908639.","journal-title":"N Engl J Med"},{"issue":"10212","key":"303_CR24","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/s0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(19)32597-8.","journal-title":"Lancet"},{"key":"303_CR25","unstructured":"FDA News Release: FDA approves new breakthrough therapy for cystic fibrosis. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-breakthrough-therapy-cystic-fibrosis (2019). Accessed 2\/16\/2023 2023."},{"issue":"1","key":"303_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1183\/09031936.00159111","volume":"40","author":"V Waters","year":"2012","unstructured":"Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012;40(1):61\u20136. https:\/\/doi.org\/10.1183\/09031936.00159111.","journal-title":"Eur Respir J"},{"issue":"8","key":"303_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ppul.23217","volume":"50","author":"J Cogen","year":"2015","unstructured":"Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, et al. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol. 2015;50(8):763\u201370. https:\/\/doi.org\/10.1002\/ppul.23217.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"303_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ppul.21374","volume":"46","author":"DB Sanders","year":"2011","unstructured":"Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46(4):393\u2013400. https:\/\/doi.org\/10.1002\/ppul.21374.","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"303_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/aje\/153.4.345","volume":"153","author":"TG Liou","year":"2001","unstructured":"Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153(4):345\u201352. https:\/\/doi.org\/10.1093\/aje\/153.4.345.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"303_CR30","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1038\/s41598-020-63590-8","volume":"10","author":"TG Liou","year":"2020","unstructured":"Liou TG, Kartsonaki C, Keogh RH, Adler FR. Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods. Sci Rep. 2020;10(1):6602. https:\/\/doi.org\/10.1038\/s41598-020-63590-8.","journal-title":"Sci Rep"},{"key":"303_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071527","author":"J Duckers","year":"2021","unstructured":"Duckers J, Lesher B, Thorat T, Lucas E, McGarry LJ, Chandarana K, et al. Real-world outcomes of ivacaftor treatment in people with cystic fibrosis: a systematic review. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10071527.","journal-title":"J Clin Med"},{"issue":"4","key":"303_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40272-022-00509-y","volume":"24","author":"JA King","year":"2022","unstructured":"King JA, Nichols AL, Bentley S, Carr SB, Davies JC. An update on CFTR modulators as new therapies for cystic fibrosis. Paediatr Drugs. 2022;24(4):321\u201333. https:\/\/doi.org\/10.1007\/s40272-022-00509-y.","journal-title":"Paediatr Drugs"},{"key":"303_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.prrv.2020.05.002","volume":"42","author":"IM Balfour-Lynn","year":"2022","unstructured":"Balfour-Lynn IM, King JA. CFTR modulator therapies\u2014effect on life expectancy in people with cystic fibrosis. Paediatr Respir Rev. 2022;42:3\u20138. https:\/\/doi.org\/10.1016\/j.prrv.2020.05.002.","journal-title":"Paediatr Respir Rev"},{"issue":"4","key":"303_CR34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","volume":"22","author":"JK Bower","year":"2023","unstructured":"Bower JK, Volkova N, Ahluwalia N, Sahota G, Xuan F, Chin A, et al. Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study. J Cyst Fibros. 2023;22(4):730\u20137. https:\/\/doi.org\/10.1016\/j.jcf.2023.03.002.","journal-title":"J Cyst Fibros"},{"key":"303_CR35","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202312-1065OC","author":"PR Burgel","year":"2024","unstructured":"Burgel PR, Paillasseur JL, Durieu I, Reynaud-Gaubert M, Hamidfar RM, Murris-Espin M, et al. Multisystemic effects of elexacaftor-tezacaftor-ivacaftor in adults with cystic fibrosis and advanced lung disease. Ann Am Thorac Soc. 2024. https:\/\/doi.org\/10.1513\/AnnalsATS.202312-1065OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"303_CR36","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ppul.26318","volume":"58","author":"KS McCoy","year":"2023","unstructured":"McCoy KS, Blind J, Johnson T, Olson P, Raterman L, Bai S, et al. Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis. Pediatr Pulmonol. 2023;58(4):1178\u201384. https:\/\/doi.org\/10.1002\/ppul.26318.","journal-title":"Pediatr Pulmonol"},{"key":"303_CR37","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01241-2023","author":"E Kerem","year":"2024","unstructured":"Kerem E, Orenti A, Adamoli A, Hatziagorou E, Naehrlich L, Sermet-Gaudelus I. Cystic fibrosis in Europe: improved lung function and longevity\u2014reasons for cautious optimism, but challenges remain. Eur Respir J. 2024. https:\/\/doi.org\/10.1183\/13993003.01241-2023.","journal-title":"Eur Respir J"},{"issue":"10","key":"303_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/thorax-2023-220558","volume":"79","author":"CA Merlo","year":"2024","unstructured":"Merlo CA, Thorat T, DerSarkissian M, McGarry LJ, Nguyen C, Gu YM, et al. Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis. Thorax. 2024;79(10):925\u201333. https:\/\/doi.org\/10.1136\/thorax-2023-220558.","journal-title":"Thorax"},{"key":"303_CR39","unstructured":"Cystic Fibrosis Foundation Patient Registry. Annual Data Report Technical Summary. Bethesda, Maryland: U.S. Cystic Fibrosis Foundation; 2018."},{"issue":"2","key":"303_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jcf.2017.11.014","volume":"17","author":"RH Keogh","year":"2018","unstructured":"Keogh RH, Stanojevic S. A guide to interpreting estimated median age of survival in cystic fibrosis patient registry reports. J Cyst Fibros. 2018;17(2):213\u20137. https:\/\/doi.org\/10.1016\/j.jcf.2017.11.014.","journal-title":"J Cyst Fibros"},{"key":"303_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jclinepi.2015.08.026","volume":"70","author":"J Sykes","year":"2016","unstructured":"Sykes J, Stanojevic S, Goss CH, Quon BS, Marshall BC, Petren K, et al. A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts. J Clin Epidemiol. 2016;70:206\u201313. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.08.026.","journal-title":"J Clin Epidemiol"},{"key":"303_CR42","unstructured":"Simon RH. Aging with CF (Symposium 8): CF, Common Co-Morbidities, and Aging. North American Cystic Fibrosis Conference: U.S. Cystic Fibrosis Foundation North American Cystic Fibrosis Conference: https:\/\/www.youtube.com\/watch?v=csjeIKAiEXc; 2022."},{"key":"303_CR43","unstructured":"Mitchell M, Muftakhidinov B, Winchen T: Engauge Digitizer Software. http:\/\/markummitchell.github.io\/engauge-digitizer Accessed Jun 29, 2023."},{"key":"303_CR44","unstructured":"Cystic Fibrosis Foundation Patient Registry. 2022 Annual Data Report. Bethesda, Maryland: U.S. Cystic Fibrosis Foundation; 2023."},{"issue":"8","key":"303_CR45","doi-asserted-by":"publisher","first-page":"537","DOI":"10.7326\/m16-0858","volume":"166","author":"AL Stephenson","year":"2017","unstructured":"Stephenson AL, Sykes J, Stanojevic S, Quon BS, Marshall BC, Petren K, et al. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med. 2017;166(8):537\u201346. https:\/\/doi.org\/10.7326\/m16-0858.","journal-title":"Ann Intern Med"},{"issue":"1","key":"303_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jcf.2010.08.021","volume":"10","author":"AD Jackson","year":"2011","unstructured":"Jackson AD, Daly L, Kelleher C, Marshall BC, Quinton HB, Foley L, et al. The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited. J Cyst Fibros. 2011;10(1):62\u20135. https:\/\/doi.org\/10.1016\/j.jcf.2010.08.021.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"303_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0022-3476(05)83478-x","volume":"122","author":"SC FitzSimmons","year":"1993","unstructured":"FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122(1):1\u20139. https:\/\/doi.org\/10.1016\/s0022-3476(05)83478-x.","journal-title":"J Pediatr"},{"issue":"5","key":"303_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0045-9380(94)90034-5","volume":"24","author":"SC FitzSimmons","year":"1994","unstructured":"FitzSimmons SC. The changing epidemiology of cystic fibrosis. Curr Probl Pediatr. 1994;24(5):171\u20139. https:\/\/doi.org\/10.1016\/0045-9380(94)90034-5.","journal-title":"Curr Probl Pediatr"},{"key":"303_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.annepidem.2023.07.008","volume":"86","author":"JS Ostrenga","year":"2023","unstructured":"Ostrenga JS, Whitney Brown A, Todd JV, Elbert A, Fink AK, Faro A, et al. Impact of loss to follow-up on survival estimation for cystic fibrosis. Ann Epidemiol. 2023;86:98\u2013103. https:\/\/doi.org\/10.1016\/j.annepidem.2023.07.008. (e5).","journal-title":"Ann Epidemiol"},{"issue":"6","key":"303_CR50","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1067\/mpd.2003.197","volume":"142","author":"M Kulich","year":"2003","unstructured":"Kulich M, Rosenfeld M, Goss CH, Wilmott R. Improved survival among young patients with cystic fibrosis. J Pediatr. 2003;142(6):631\u20136. https:\/\/doi.org\/10.1067\/mpd.2003.197.","journal-title":"J Pediatr"},{"issue":"1","key":"303_CR51","doi-asserted-by":"publisher","first-page":"19748","DOI":"10.1038\/s41598-022-24374-4","volume":"12","author":"R Ruseckaite","year":"2022","unstructured":"Ruseckaite R, Salimi F, Earnest A, Bell SC, Douglas T, Frayman K, et al. Survival of people with cystic fibrosis in Australia. Sci Rep. 2022;12(1):19748. https:\/\/doi.org\/10.1038\/s41598-022-24374-4.","journal-title":"Sci Rep"},{"issue":"3","key":"303_CR52","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jcf.2006.07.001","volume":"6","author":"G Bellis","year":"2007","unstructured":"Bellis G, Cazes MH, Parant A, Gaimard M, Travers C, Le Roux E, et al. Cystic fibrosis mortality trends in France. J Cyst Fibros. 2007;6(3):179\u201386. https:\/\/doi.org\/10.1016\/j.jcf.2006.07.001.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"303_CR53","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1183\/09031936.00119714","volume":"45","author":"AL Stephenson","year":"2015","unstructured":"Stephenson AL, Tom M, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA, et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J. 2015;45(3):670\u20139. https:\/\/doi.org\/10.1183\/09031936.00119714.","journal-title":"Eur Respir J"},{"issue":"10","key":"303_CR54","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/oxfordjournals.aje.a008664","volume":"143","author":"M Corey","year":"1996","unstructured":"Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970\u20131989. Am J Epidemiol. 1996;143(10):1007\u201317. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a008664.","journal-title":"Am J Epidemiol"},{"issue":"10","key":"303_CR55","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s10038-023-01160-2","volume":"68","author":"Y Kozawa","year":"2023","unstructured":"Kozawa Y, Yamamoto A, Nakakuki M, Fujiki K, Kondo S, Okada T, et al. Clinical and genetic features of cystic fibrosis in Japan. J Hum Genet. 2023;68(10):671\u201380. https:\/\/doi.org\/10.1038\/s10038-023-01160-2.","journal-title":"J Hum Genet"},{"issue":"3","key":"303_CR56","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/thorax-2022-219086","volume":"78","author":"A Coriati","year":"2023","unstructured":"Coriati A, Ma X, Sykes J, Stanojevic S, Ruseckaite R, Lemonnier L, et al. Beyond borders: cystic fibrosis survival between Australia, Canada, France and New Zealand. Thorax. 2023;78(3):242\u20138. https:\/\/doi.org\/10.1136\/thorax-2022-219086.","journal-title":"Thorax"},{"issue":"2","key":"303_CR57","doi-asserted-by":"publisher","DOI":"10.36416\/1806-3756\/e20200166","volume":"47","author":"AH Santo","year":"2021","unstructured":"Santo AH, Silva-Filho L. Cystic fibrosis-related mortality trends in Brazil for the 1999\u20132017 period: a multiple-cause-of-death study. J Bras Pneumol. 2021;47(2): e20200166. https:\/\/doi.org\/10.36416\/1806-3756\/e20200166.","journal-title":"J Bras Pneumol"},{"issue":"1","key":"303_CR58","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1038\/s41598-023-41868-x","volume":"13","author":"H Singh","year":"2023","unstructured":"Singh H, Jani C, Marshall DC, Franco R, Bhatt P, Podder S, et al. Cystic fibrosis-related mortality in the United States from 1999 to 2020: an observational analysis of time trends and disparities. Sci Rep. 2023;13(1):15030. https:\/\/doi.org\/10.1038\/s41598-023-41868-x.","journal-title":"Sci Rep"},{"issue":"4","key":"303_CR59","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/ppul.25810","volume":"57","author":"M Zampoli","year":"2022","unstructured":"Zampoli M, Kassanjee R, Verstraete J, Westwood A, Zar HJ, Morrow BM. Trends in cystic fibrosis survival over 40 years in South Africa: An observational cohort study. Pediatr Pulmonol. 2022;57(4):908\u201318. https:\/\/doi.org\/10.1002\/ppul.25810.","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"303_CR60","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/ppul.25351","volume":"56","author":"AE Bustamante","year":"2021","unstructured":"Bustamante AE, Fern\u00e1ndez LT, Rivas LC, Mercado-Longoria R. Disparities in cystic fibrosis survival in Mexico: Impact of socioeconomic status. Pediatr Pulmonol. 2021;56(6):1566\u201372. https:\/\/doi.org\/10.1002\/ppul.25351.","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"303_CR61","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jcf.2014.07.010","volume":"14","author":"G Alicandro","year":"2015","unstructured":"Alicandro G, Frova L, Di Fraia G, Colombo C. Cystic fibrosis mortality trend in Italy from 1970 to 2011. J Cyst Fibros. 2015;14(2):267\u201374. https:\/\/doi.org\/10.1016\/j.jcf.2014.07.010.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"303_CR62","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jcf.2013.12.002","volume":"13","author":"MN Hurley","year":"2014","unstructured":"Hurley MN, McKeever TM, Prayle AP, Fogarty AW, Smyth AR. Rate of improvement of CF life expectancy exceeds that of general population\u2013observational death registration study. J Cyst Fibros. 2014;13(4):410\u20135. https:\/\/doi.org\/10.1016\/j.jcf.2013.12.002.","journal-title":"J Cyst Fibros"},{"issue":"8","key":"303_CR63","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10654-008-9263-1","volume":"23","author":"E Ramalle-Gomara","year":"2008","unstructured":"Ramalle-Gomara E, Perucha M, Gonz\u00e1lez MA, Qui\u00f1ones C, Andr\u00e9s J, Posada M. Cystic fibrosis mortality trends in Spain among infants and young children: 1981\u20132004. Eur J Epidemiol. 2008;23(8):523\u20139. https:\/\/doi.org\/10.1007\/s10654-008-9263-1.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"303_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1183\/09031936.00056507","volume":"31","author":"M Stern","year":"2008","unstructured":"Stern M, Wiedemann B, Wenzlaff P. From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995 2006. Eur Respir J. 2008;31(1):29\u201335. https:\/\/doi.org\/10.1183\/09031936.00056507.","journal-title":"Eur Respir J"},{"issue":"9","key":"303_CR65","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1053\/rmed.2002.1329","volume":"96","author":"L Lannefors","year":"2002","unstructured":"Lannefors L, Lindgren A. Demographic transition of the Swedish cystic fibrosis community\u2013results of modern care. Respir Med. 2002;96(9):681\u20135. https:\/\/doi.org\/10.1053\/rmed.2002.1329.","journal-title":"Respir Med"},{"issue":"6","key":"303_CR66","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1378\/chest.117.6.1656","volume":"117","author":"A Fogarty","year":"2000","unstructured":"Fogarty A, Hubbard R, Britton J. International comparison of median age at death from cystic fibrosis. Chest. 2000;117(6):1656\u201360. https:\/\/doi.org\/10.1378\/chest.117.6.1656.","journal-title":"Chest"},{"issue":"11","key":"303_CR67","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1001\/archpedi.1996.02170360071012","volume":"150","author":"CS Halliburton","year":"1996","unstructured":"Halliburton CS, Mannino DM, Olney RS. Cystic fibrosis deaths in the United States from 1979 through 1991. An analysis using multiple-cause mortality data. Arch Pediatr Adolesc Med. 1996;150(11):1181\u20135. https:\/\/doi.org\/10.1001\/archpedi.1996.02170360071012.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"303_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13040763","author":"LVF de Azevedo","year":"2023","unstructured":"de Azevedo LVF, Cruz F, Martins JP, Marson FAL. Cystic fibrosis: a descriptive analysis of deaths in a two-decade period in Brazil according to age, race, and sex. Diagnostics (Basel). 2023. https:\/\/doi.org\/10.3390\/diagnostics13040763.","journal-title":"Diagnostics (Basel)."},{"issue":"4","key":"303_CR69","first-page":"233","volume":"29","author":"RB Singer","year":"1997","unstructured":"Singer RB. Cystic fibrosis mortality: registry data of cystic fibrosis. J Insur Med. 1997;29(4):233\u20139.","journal-title":"J Insur Med"},{"issue":"3","key":"303_CR70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/(sici)1099-0496(199603)21:3<153::Aid-ppul1>3.0.Co;2-r","volume":"21","author":"B Frederiksen","year":"1996","unstructured":"Frederiksen B, Lanng S, Koch C, H\u00f8iby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol. 1996;21(3):153\u20138. https:\/\/doi.org\/10.1002\/(sici)1099-0496(199603)21:3%3c153::Aid-ppul1%3e3.0.Co;2-r.","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"303_CR71","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1164\/rccm.201707-1541OC","volume":"197","author":"CH Goss","year":"2018","unstructured":"Goss CH, Sykes J, Stanojevic S, Marshall B, Petren K, Ostrenga J, et al. Comparison of nutrition and lung function outcomes in patients with cystic fibrosis living in Canada and the United States. Am J Respir Crit Care Med. 2018;197(6):768\u201375. https:\/\/doi.org\/10.1164\/rccm.201707-1541OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"303_CR72","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/02770906809100345","volume":"5","author":"WJ Warwick","year":"1968","unstructured":"Warwick WJ, Pogue RE. The prognosis for children with cystic fibrosis based on reasoned approaches to therapy: past, present, and future. J Asthma Res. 1968;5(4):277\u201384. https:\/\/doi.org\/10.3109\/02770906809100345.","journal-title":"J Asthma Res"},{"issue":"6","key":"303_CR73","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","volume":"41","author":"M Corey","year":"1988","unstructured":"Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988;41(6):583\u201391. https:\/\/doi.org\/10.1016\/0895-4356(88)90063-7.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"303_CR74","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1651-2227.1988.tb10765.x","volume":"77","author":"OH Nielsen","year":"1988","unstructured":"Nielsen OH, Thomsen BL, Green A, Andersen PK, Hauge M, Schi\u00f8tz PO. Cystic fibrosis in Denmark 1945 to 1985. An analysis of incidence, mortality and influence of centralized treatment on survival. Acta Paediatr Scand. 1988;77(6):836\u201341. https:\/\/doi.org\/10.1111\/j.1651-2227.1988.tb10765.x.","journal-title":"Acta Paediatr Scand"},{"key":"303_CR75","doi-asserted-by":"publisher","unstructured":"Cystic fibrosis in the United Kingdom 1977\u201385: an improving picture. British Paediatric Association Working Party on Cystic Fibrosis. Bmj. 1988;297(6663):1599\u2013602. https:\/\/doi.org\/10.1136\/bmj.297.6663.1599.","DOI":"10.1136\/bmj.297.6663.1599"},{"key":"303_CR76","unstructured":"US CF Foundation: All Fifty States to Screen Newborns for Cystic Fibrosis by 2010. https:\/\/www.cff.org\/node\/766 (2009). Accessed 2023."},{"issue":"Rr-13","key":"303_CR77","first-page":"1","volume":"53","author":"SD Grosse","year":"2004","unstructured":"Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(Rr-13):1\u201336.","journal-title":"MMWR Recomm Rep"},{"issue":"10","key":"303_CR78","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamapediatrics.2022.2674","volume":"176","author":"M Rosenfeld","year":"2022","unstructured":"Rosenfeld M, Ostrenga J, Cromwell EA, Magaret A, Szczesniak R, Fink A, et al. Real-world associations of US cystic fibrosis newborn screening programs with nutritional and pulmonary outcomes. JAMA Pediatr. 2022;176(10):990\u20139. https:\/\/doi.org\/10.1001\/jamapediatrics.2022.2674.","journal-title":"JAMA Pediatr"},{"issue":"3 Suppl","key":"303_CR79","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.jpeds.2005.08.014","volume":"147","author":"HJ Lai","year":"2005","unstructured":"Lai HJ, Cheng Y, Farrell PM. The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: evidence from the United States Cystic Fibrosis Foundation registry data. J Pediatr. 2005;147(3 Suppl):S57-63. https:\/\/doi.org\/10.1016\/j.jpeds.2005.08.014.","journal-title":"J Pediatr"},{"issue":"12","key":"303_CR80","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/archdischild-2011-300449","volume":"96","author":"FN Dijk","year":"2011","unstructured":"Dijk FN, McKay K, Barzi F, Gaskin KJ, Fitzgerald DA. Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre. Arch Dis Child. 2011;96(12):1118\u201323. https:\/\/doi.org\/10.1136\/archdischild-2011-300449.","journal-title":"Arch Dis Child"},{"issue":"6","key":"303_CR81","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/aje\/kwh083","volume":"159","author":"HJ Lai","year":"2004","unstructured":"Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol. 2004;159(6):537\u201346. https:\/\/doi.org\/10.1093\/aje\/kwh083.","journal-title":"Am J Epidemiol"},{"key":"303_CR82","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00109-2017","author":"G Tridello","year":"2018","unstructured":"Tridello G, Castellani C, Meneghelli I, Tamanini A, Assael BM. Early diagnosis from newborn screening maximises survival in severe cystic fibrosis. ERJ Open Res. 2018. https:\/\/doi.org\/10.1183\/23120541.00109-2017.","journal-title":"ERJ Open Res"},{"issue":"5","key":"303_CR83","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/aje\/kwf064","volume":"156","author":"BM Assael","year":"2002","unstructured":"Assael BM, Castellani C, Ocampo MB, Iansa P, Callegaro A, Valsecchi MG. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. Am J Epidemiol. 2002;156(5):397\u2013401. https:\/\/doi.org\/10.1093\/aje\/kwf064.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"303_CR84","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jcf.2020.06.002","volume":"20","author":"CB Barreda","year":"2021","unstructured":"Barreda CB, Farrell PM, Laxova A, Eickhoff JC, Braun AT, Coller RJ, et al. Newborn screening alone insufficient to improve pulmonary outcomes for cystic fibrosis. J Cyst Fibros. 2021;20(3):492\u20138. https:\/\/doi.org\/10.1016\/j.jcf.2020.06.002.","journal-title":"J Cyst Fibros"},{"issue":"8","key":"303_CR85","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","volume":"73","author":"L Bessonova","year":"2018","unstructured":"Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018;73(8):731\u201340. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210394.","journal-title":"Thorax"},{"issue":"1","key":"303_CR86","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","volume":"6","author":"M Higgins","year":"2020","unstructured":"Higgins M, Volkova N, Moy K, Marshall BC, Bilton D. Real-world outcomes among patients with cystic fibrosis treated with Ivacaftor: 2012\u20132016 experience. Pulm Ther. 2020;6(1):141\u20139. https:\/\/doi.org\/10.1007\/s41030-020-00115-8.","journal-title":"Pulm Ther"},{"issue":"4","key":"303_CR87","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccm.2022.06.009","volume":"43","author":"AH Gifford","year":"2022","unstructured":"Gifford AH, Taylor-Cousar JL, Davies JC, McNally P. Update on clinical outcomes of highly effective modulator therapy. Clin Chest Med. 2022;43(4):677\u201395. https:\/\/doi.org\/10.1016\/j.ccm.2022.06.009.","journal-title":"Clin Chest Med"},{"key":"303_CR88","doi-asserted-by":"crossref","unstructured":"Merlo C, Romdhani H, DerSarkissian M, Muthukumar A, McGarry LJ, Lou Y, et al. Clinical outcomes in concurrent elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) treated vs.ineligible cohorts in the US Cystic Fibrosis Foundation Patient Registry (CFFPR) during COVID-19. Presented at the 47th European Cystic Fibrosis Society (ECFS) Conference 2024.","DOI":"10.1016\/S1569-1993(24)00264-9"},{"key":"303_CR89","doi-asserted-by":"publisher","first-page":"175346661882018","DOI":"10.1177\/1753466618820186","volume":"13","author":"JL Rubin","year":"2019","unstructured":"Rubin JL, O\u2019Callaghan L, Pelligra C, Konstan MW, Ward A, Ishak JK, et al. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor\/ivacaftor. Ther Adv Respir Dis. 2019;13:1753466618820186. https:\/\/doi.org\/10.1177\/1753466618820186.","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"303_CR90","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/13696998.2022.2077550","volume":"25","author":"JL Rubin","year":"2022","unstructured":"Rubin JL, Lopez A, Booth J, Gunther P, Jena AB. Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis. J Med Econ. 2022;25(1):783\u201391. https:\/\/doi.org\/10.1080\/13696998.2022.2077550.","journal-title":"J Med Econ"},{"key":"303_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.02.004","author":"A Lopez","year":"2023","unstructured":"Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros. 2023. https:\/\/doi.org\/10.1016\/j.jcf.2023.02.004.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"303_CR92","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jcf.2020.07.017","volume":"20","author":"S Stanojevic","year":"2021","unstructured":"Stanojevic S, Vukovojac K, Sykes J, Ratjen F, Tullis E, Stephenson AL. Projecting the impact of delayed access to elexacaftor\/tezacaftor\/ivacaftor for people with Cystic Fibrosis. J Cyst Fibros. 2021;20(2):243\u20139. https:\/\/doi.org\/10.1016\/j.jcf.2020.07.017.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"303_CR93","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1183\/13993003.01444-2015","volume":"47","author":"P Dilokthornsakul","year":"2016","unstructured":"Dilokthornsakul P, Hansen RN, Campbell JD. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation. Eur Respir J. 2016;47(6):1697\u2013705. https:\/\/doi.org\/10.1183\/13993003.01444-2015.","journal-title":"Eur Respir J"},{"issue":"10","key":"303_CR94","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jval.2017.06.014","volume":"20","author":"P Dilokthornsakul","year":"2017","unstructured":"Dilokthornsakul P, Patidar M, Campbell JD. Forecasting the long-term clinical and economic outcomes of lumacaftor\/ivacaftor in cystic fibrosis patients with homozygous phe508del mutation. Value Health. 2017;20(10):1329\u201335. https:\/\/doi.org\/10.1016\/j.jval.2017.06.014.","journal-title":"Value Health"},{"issue":"4","key":"303_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283479","volume":"18","author":"LJ McGarry","year":"2023","unstructured":"McGarry LJ, Bhaiwala Z, Lopez A, Chandler C, Pelligra CG, Rubin JL, et al. Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data. PLoS\u00a0One. 2023;18(4): e0283479. https:\/\/doi.org\/10.1371\/journal.pone.0283479.","journal-title":"PLoS\u00a0One"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00303-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00303-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00303-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T10:37:03Z","timestamp":1755859023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00303-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00303-4","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jaime L. Rubin, Craig McKinnon and Gabriel Ghizzi Pedra are employees of Vertex Pharmaceuticals Incorporated and may own stocks\/stock options in the company. Devon A. Morgan and Kimberly Zweig have received consultancy fees from Vertex Pharmaceuticals Incorporated. Theodore G. Liou is an employee of the University of Utah which received funding from Vertex for this project. Theodore G. Liou is supported by the NIH\/NHLBI (R01 HL125520), the Cystic Fibrosis Foundation, Bethesda, MD (grants CC-132-16AD, LIOU13A0, LIOU14Y0, and LIOU14Y4), the Ben B. and Iris M. Margolis Family Foundation of Utah, and the Claudia Ruth Goodrich Stevens Endowment Fund.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This is a comprehensive narrative literature review and peer-reviewed articles were identified using PubMed. Additionally, a secondary analysis was conducted using recent longitudinal data from the U.S. CFFPR. The U.S. CFFPR collects prospective data on consenting people with CF. Internal Review Board (IRB) approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}